Starpharma (SPHRY) Stock Price, News & Analysis

Company Overview

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Key Stats

• Today's Range: $0.56 to $0.56
• 50-Day Range: $0.47 to $0.65
• 52-Week Range: $0.47 to $0.84
• Volume: N/A
• Average Volume: 1,587 shs
• Market Capitalization: $23.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SPHRY Stock Analysis - Frequently Asked Questions

How have SPHRY shares performed this year?

Starpharma's stock was trading at $0.6433 at the start of the year. Since then, SPHRY stock has decreased by 12.7% and is now trading at $0.5614.
View the best growth stocks for 2025 here.

How do I buy shares of Starpharma?

Shares of SPHRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/27/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SPHRY
• CIK: N/A
• Web: www.starpharma.com
• Phone: (138) 532-2700
• Fax: 61-3-9510-5955
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 4.94
• Quick Ratio: 4.58

Sales & Book Value

• Annual Sales: $6.40 million
• Price / Sales: 3.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.45 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 41,822,000
• Free Float: N/A
• Market Cap: $23.48 million
• Optionable: Not Optionable
• Beta: 0.80